Chemoradiotherapy effcacy in squamous cell rectal cancer: a propensity score matched analysis

Q4 Medicine

Siberian journal of oncology Pub Date : 2023-09-05 DOI:10.21294/1814-4861-2023-22-4-14-21

V. V. Murzo, S. S. Gordeev, V. S. Myshlyakov, Z. Z. Mamedli

{"title":"Chemoradiotherapy effcacy in squamous cell rectal cancer: a propensity score matched analysis","authors":"V. V. Murzo, S. S. Gordeev, V. S. Myshlyakov, Z. Z. Mamedli","doi":"10.21294/1814-4861-2023-22-4-14-21","DOIUrl":null,"url":null,"abstract":"Introduction . Sporadic cases of squamous cell carcinoma of the rectum (rSCC) do not allow a comparative characterization of tumor aggressiveness and its response to chemoradiotherapy in relation to more common squamous cell entities, in particular, anal squamous cell carcinoma (aSCC). Objective : comparative evaluation of the short- and long-term results of chemoradiation therapy in patients with rSCC and aSCC. Material and Methods . In this retrospective study we included patients with nonmetastatic squamous cell carcinoma of the rectum (rSCC) and anal canal squamous cell carcinoma (aSCC) who received chemoradiotherapy and compared them in a 1:1 ratio using propensity-score matching. The dynamics of tumor response to treatment were compared by Kaplan-Meier survival analysis (OS and RFS) followed by Log-Rank verifcation, rate of complete response after 6 months. Results . A total of 15 pairs of matched patients were evaluated. Patients in both groups had reliably similar sex, age, histological grade, initial primary tumor size, differing only in tumor histological subtype. In the aSCC group, 60 % of patients had metastases to pelvic lymph nodes, while in the rSCC group metastases had 46.67 % (p=1). The median follow-up was 44 months. The 3-year OS in the aSCC group of patients was 76.9 %, and 71.4 % in the rSCC group (p=0.567). The 3-year DFS in the aSCC group was 66.7 %, and in the rSCC group 34.7 % (p=0.406). The rate of achieving complete clinical response to CRT after 6 months was 86.7 % for the aSCC group and only 46.7 % for the rSCC group (p=0.05). Organ-saving treatment was achieved in 93.3 % of aSCC patients and 73.3 % of rSCC patients (p=0.33). Conclusion . Overall and recurrence-free survival rates were not signifcantly decreased for rSCC patients relative to aSCC patients. This indicates a similar course and prognosis in the two diseases, but rSCC is characterized by a signifcantly lower rate of complete response to treatment.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":"75 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Siberian journal of oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21294/1814-4861-2023-22-4-14-21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction . Sporadic cases of squamous cell carcinoma of the rectum (rSCC) do not allow a comparative characterization of tumor aggressiveness and its response to chemoradiotherapy in relation to more common squamous cell entities, in particular, anal squamous cell carcinoma (aSCC). Objective : comparative evaluation of the short- and long-term results of chemoradiation therapy in patients with rSCC and aSCC. Material and Methods . In this retrospective study we included patients with nonmetastatic squamous cell carcinoma of the rectum (rSCC) and anal canal squamous cell carcinoma (aSCC) who received chemoradiotherapy and compared them in a 1:1 ratio using propensity-score matching. The dynamics of tumor response to treatment were compared by Kaplan-Meier survival analysis (OS and RFS) followed by Log-Rank verifcation, rate of complete response after 6 months. Results . A total of 15 pairs of matched patients were evaluated. Patients in both groups had reliably similar sex, age, histological grade, initial primary tumor size, differing only in tumor histological subtype. In the aSCC group, 60 % of patients had metastases to pelvic lymph nodes, while in the rSCC group metastases had 46.67 % (p=1). The median follow-up was 44 months. The 3-year OS in the aSCC group of patients was 76.9 %, and 71.4 % in the rSCC group (p=0.567). The 3-year DFS in the aSCC group was 66.7 %, and in the rSCC group 34.7 % (p=0.406). The rate of achieving complete clinical response to CRT after 6 months was 86.7 % for the aSCC group and only 46.7 % for the rSCC group (p=0.05). Organ-saving treatment was achieved in 93.3 % of aSCC patients and 73.3 % of rSCC patients (p=0.33). Conclusion . Overall and recurrence-free survival rates were not signifcantly decreased for rSCC patients relative to aSCC patients. This indicates a similar course and prognosis in the two diseases, but rSCC is characterized by a signifcantly lower rate of complete response to treatment.

查看原文本刊更多论文

放化疗在鳞状细胞直肠癌中的疗效:倾向评分匹配分析

介绍。散发性的直肠鳞状细胞癌(rSCC)不能比较肿瘤的侵袭性及其对放化疗的反应，与更常见的鳞状细胞实体，特别是肛门鳞状细胞癌(aSCC)相比。目的:比较评价rSCC和aSCC患者放化疗的短期和长期效果。材料和方法。在这项回顾性研究中，我们纳入了接受放化疗的直肠非转移性鳞状细胞癌(rSCC)和肛管鳞状细胞癌(aSCC)患者，并使用倾向评分匹配以1:1的比例对它们进行比较。采用Kaplan-Meier生存分析(OS和RFS)比较肿瘤对治疗反应的动态，然后进行Log-Rank验证，6个月后完全缓解率。结果。共对15对匹配的患者进行评估。两组患者的性别、年龄、组织学分级、初始原发肿瘤大小可靠相似，仅在肿瘤组织学亚型上有所不同。在aSCC组中，60%的患者转移到盆腔淋巴结，而在rSCC组中转移率为46.67% (p=1)。中位随访时间为44个月。aSCC组患者的3年OS为76.9%，rSCC组为71.4% (p=0.567)。aSCC组3年DFS为66.7%，rSCC组为34.7% (p=0.406)。6个月后，aSCC组临床完全缓解率为86.7%，rSCC组仅为46.7% (p=0.05)。93.3%的aSCC患者和73.3%的rSCC患者实现了器官保存治疗(p=0.33)。结论。与aSCC患者相比，rSCC患者的总生存率和无复发生存率没有显著降低。这表明两种疾病的病程和预后相似，但rSCC的特点是对治疗的完全缓解率明显较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Siberian journal of oncology Medicine-Oncology

CiteScore

0.40

自引率

0.00%

发文量

117

审稿时长

8 weeks

期刊介绍： The main objectives of the journal are: -to promote the establishment of Russia’s leading worldwide positions in the field of experimental and clinical oncology- to create the international discussion platform intended to cover all aspects of basic and clinical cancer research, including carcinogenesis, molecular biology, epidemiology, cancer prevention, diagnosis and multimodality treatment (surgery, chemotherapy, radiation therapy, hormone therapy), anesthetic management, medical and social rehabilitation, palliative care as well as the improvement of life quality of cancer patients- to encourage promising young scientists to be actively involved in cancer research programs- to provide a platform for researches and doctors all over the world to promote, share, and discuss various new issues and developments in cancer related problems. (to create a communication platform for the expansion of cooperation between Russian and foreign professional associations).- to provide the information about the latest worldwide achievements in different fields of oncology The most important tasks of the journal are: -to encourage scientists to publish their research results- to offer a forum for active discussion on topics of major interest - to invite the most prominent Russian and foreign authors to share their latest research findings with cancer research community- to promote the exchange of research information, clinical experience, current trends and the recent developments in the field of oncology as well as to review interesting cases encountered by colleagues all over the world- to expand the editorial board and reviewers with the involvement of well-known Russian and foreign experts- to provide open access to full text articles- to include the journal into the international database- to increase the journal’s impact factor- to promote the journal to the International and Russian markets